Syndax Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.33.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Syndax Pharmaceuticals Inc is 7.02, ranking 139 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 64.86M, representing a year-over-year increase of 223.64%, while its net profit experienced a year-over-year increase of 49.71%.
Key Metrics
The current valuation score of Syndax Pharmaceuticals Inc is 6.06, ranking 327 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.48, which is -70.00% below the recent high of -2.24 and -57.69% above the recent low of -11.79.
The current earnings forecast score of Syndax Pharmaceuticals Inc is 8.86, ranking 46 out of 383 in the Biotechnology & Medical Research industry. The average price target is 38.00, with a high of 56.00 and a low of 27.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Syndax Pharmaceuticals Inc is 7.18, ranking 134 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 23.98 and the support level at 18.40, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Syndax Pharmaceuticals Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.04%, representing a quarter-over-quarter increase of 3.63%. The largest institutional shareholder is Steven Cohen, holding a total of 4.88M shares, representing 5.51% of shares outstanding, with 18.26% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Syndax Pharmaceuticals Inc is 5.56, ranking 42 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Syndax Pharmaceuticals Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
